|Mr. Michael V. Ward||Pres & CEO||N/A||N/A||1957|
|Mr. James Clavijo||CFO & Sec.||N/A||N/A||1966|
|Mr. Paul Burroughs||Director of Communications||N/A||N/A||N/A|
|Dr. Nicola Ammer||Chief Medical Officer & VP of Clinical Devel.||N/A||N/A||N/A|
|Mr. Brian Garrison||Sr. VP of Global Commercial Operations||N/A||N/A||N/A|
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. It also has a collaboration agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for the development, manufacture, and commercialization of Zoptrex, which has completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer in the People's Republic of China. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.
Aeterna Zentaris Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.